About LYNPARZA in prostate cancer
About LYNPARZA® (olaparib) in prostate cancer
Great Britain prescribing information
Northern Ireland prescribing information
Introducing the first licensed PARPi in metastatic castration-resistant prostate cancer (mCRPC)1
LYNPARZA is indicated:
- as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.1
- in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated.1
To find out more about LYNPARZA Monotherapy click here:
PDF, 1.38 MB
LYNPARZA Monotherapy is now reimbursed by NHSE and SMC2,3
To find out more about LYNPARZA in combination with abiraterone click here:
PDF, 1.53 MB
LYNPARZA – Contact us
If you would like to keep updated about LYNPARZA in prostate cancer please fill in the contact form below.
This form is not intended for the reporting of adverse events or medical information. Please see the footer of the page for details on how to report adverse events.
References
- LYNPARZA (olaparib). Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/9488/smpc.
- NICE Final appraisal document: Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer. April 2023. Available at: https://www.nice.org.uk/guidance/gid-ta11314/documents/final-appraisal-determination-document.
- SMC Medicines Advice Olaparib. Available at: https://www.scottishmedicines.org.uk/medicines-advice/olaparib-lynparza-full-smc2366/.
Supporting documentation
100 mg and 150 mg film coated tablets – Great Britain
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet
100 mg and 150 mg film coated tablets – Northern Ireland
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet
